Janney Montgomery Scott LLC Grows Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Janney Montgomery Scott LLC grew its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 6.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,490,986 shares of the company’s stock after acquiring an additional 90,661 shares during the period. Janney Montgomery Scott LLC’s holdings in Teva Pharmaceutical Industries were worth $32,861,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in TEVA. UMB Bank n.a. lifted its stake in shares of Teva Pharmaceutical Industries by 555.6% during the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after purchasing an additional 2,067 shares in the last quarter. Smithfield Trust Co boosted its holdings in Teva Pharmaceutical Industries by 55.7% in the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after acquiring an additional 980 shares during the period. Wilmington Savings Fund Society FSB acquired a new stake in Teva Pharmaceutical Industries in the third quarter valued at approximately $50,000. Claro Advisors LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the third quarter valued at approximately $52,000. Finally, Venturi Wealth Management LLC acquired a new position in shares of Teva Pharmaceutical Industries during the third quarter worth $60,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the transaction, the executive vice president now directly owns 44,104 shares in the company, valued at $744,034.48. The trade was a 30.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Roberto Mignone sold 286,000 shares of the stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the sale, the director now owns 695,000 shares in the company, valued at $15,296,950. The trade was a 29.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.55% of the stock is owned by insiders.

Teva Pharmaceutical Industries Stock Down 1.2 %

Shares of NYSE TEVA opened at $21.75 on Friday. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. Teva Pharmaceutical Industries Limited has a twelve month low of $11.48 and a twelve month high of $22.80. The business has a 50 day simple moving average of $19.53 and a 200-day simple moving average of $18.32.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on TEVA shares. StockNews.com lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Barclays lifted their target price on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 18th. UBS Group increased their price target on Teva Pharmaceutical Industries from $28.00 to $30.00 and gave the company a “buy” rating in a report on Thursday. JPMorgan Chase & Co. lifted their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, October 21st. Finally, Piper Sandler increased their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $22.63.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.